Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
· Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
· Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).
Lund, Sweden, 11 February 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its Q4 2025 and full-year financial results.
Renée Aguiar-Lucander, CEO, Hansa Biopharma said, “Q4 capped a strong year for Hansa Biopharma. Filing our BLA with the FDA just three months after announcing Phase 3 results highlights the strength of our team and execution focus. We delivered solid growth in Europe, advanced market access efforts, and made the strategic decision to progress our next‑generation enzyme HNSA‑5487 in Guillain‑Barré syndrome, with FDA interactions planned for the first half of 2026. As we enter 2026, our focus is clear: secure FDA approval, ensure a successful U.S. launch of imlifidase, and progress commercial adoption across Europe.”
